The Gel Is To Be Delivered Via The Skin And Absorbed Into A Patient’s Circulatory System.

This medication is aimed at targeting different receptors in the body, to treat pain in an unconventional, yet more effective, manner. Up to now, Cara’s core product has shown favorable results in phase 2 clinical trials for pain relief, and does not elicit the usual side effects patients would normally experience when using opioids such as hydrocodone, morphine, and non-steroidal anti-inflammatories. Two more candidates for combination therapies come from Zynerba Pharmaceuticals ZYNE, +0.70% ZYN001 and ZYN002 are both being evaluated in various therapeutic indications at the moment. ZYN001, Marijuana Stocks a pro-drug patch that comprises of THC, is aimed at enabling transdermal delivery via a person’s skin and into their circulatory system. ZYN002, a CBD gel, is the first of its kind and is designed to act as a non-psychoactive cannabinoid. The gel is to be delivered via the skin and absorbed into a patient’s circulatory system. At present, the gel is in phase 2 of clinical development, with patients who suffer with osteoarthritis of the knee, refractory epilepsy, and Fragile X Syndrome. Focused on the development and commercialization of innovative therapies that improve the quality of life of patients, Insys Therapeutics INSY, -4.37% is developing a pipeline of products intending to address unmet medical needs and clinical shortcomings of existing commercial products. The Drug Enforcement Agency recently issued a provisional final ruling that is to result in Insys’ SYNDROS being placed in Schedule II of the Controlled Substances Act.

To read more visit http://www.marketwatch.com/story/pain-reducing-combination-therapies-proving-successful-thanks-to-innovative-specialty-pharma-players-2017-03-30

Comments are closed.